Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus

Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus

Background Randomized controlled trials showed that newer glucose‐lowering agents are cardioprotective, but most participants were men. It is unknown whether benefits are similar in women. Methods and Results Among adults with type 2 diabetes mellitus not controlled with metformin with no prior use...

Full description

Bibliographic Details
Main Authors:	Valeria Raparelli, Malik Elharram, Cristiano S. Moura, Michal Abrahamowicz, Sasha Bernatsky, Hassan Behlouli, Louise Pilote
Format:	Article
Language:	English
Published:	Wiley 2020-01-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:	glucose‐lowering agents major cardiovascular events population‐based analysis sex type 2 diabetes mellitus
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.119.012940

Similar Items

Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy
by: Cristiano S. Moura, et al.
Published: (2018-01-01)

Sex Differences in the Effectiveness of Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril–Valsartan for the Treatment of Heart Failure
by: Zahra N. Sohani, et al.
Published: (2023-07-01)

Newer glucose‐lowering drugs reduce the risk of late‐onset seizure and epilepsy: A meta‐analysis
by: Udeept Sindhu, et al.
Published: (2024-12-01)

Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose‐Lowering Drugs: A Meta‐Analysis of Randomized Outcome Trials
by: Huilin Tang, et al.
Published: (2023-05-01)

Circulating selenoprotein P levels predict glucose‐lowering and insulinotropic effects of metformin, but not alogliptin: A post‐hoc analysis
by: Yumie Takeshita, et al.
Published: (2023-02-01)

Relative effectiveness of influenza vaccines in elderly persons in the United States, 2012/2013-2017/2018 seasons
by: Marina Amaral de Avila Machado, et al.
Published: (2021-08-01)

Comparison of safety and efficacy of glimepiride-metformin and vildagliptin- metformin treatment in newly diagnosed type 2 diabetic patients
by: Surendra Kumar
Published: (2021-01-01)

Low Glucose Enhances Sensitivity of Cancer to Metformin
by: ZHANG Jie, et al.
Published: (2018-03-01)

Major adverse cardiovascular events’ reduction and their association with glucose‐lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records
by: Haowen Hsu, et al.
Published: (2024-10-01)

Real‐world risk of lower‐limb amputation associated with sodium–glucose cotransporter 2 inhibitors versus metformin: A propensity score‐matched model analysis in Japan
by: Gen Mizutani, et al.
Published: (2022-12-01)

THE ICET-A RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF DISTURBANCES OF GLUCOSE HOMEOSTASIS IN THALASSEMIA MAJOR PATIENTS
by: Vincenzo De Sanctis
Published: (2016-10-01)

Detection of glycemic abnormalities in adolescents with beta thalassemia using continuous glucose monitoring and oral glucose tolerance in adolescents and young adults with β-thalassemia major: Pilot study
by: Ashraf T Soliman, et al.
Published: (2013-01-01)

Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in patients with thalassemia major in Iran: A meta-analysis
by: Kourosh Sayemiri, et al.
Published: (2017-01-01)

Metformin-Associated Gastrointestinal Adverse Events Are Reduced by Probiotics: A Meta-Analysis
by: Izabela Szymczak-Pajor, et al.
Published: (2024-07-01)

Effects of fructose added to an oral glucose tolerance test on plasma glucose excursions in healthy adults
by: Amée M. Buziau, et al.
Published: (2023-06-01)

The Gut Microbiota-Related Antihyperglycemic Effect of Metformin
by: Izabela Szymczak-Pajor, et al.
Published: (2025-01-01)

Significant promotion of MgOy in bifunctional Pt-WOx-MgOy catalysts for the chemoselective conversion of glucose to lower polyols
by: Shuang Luo, et al.
Published: (2023-02-01)

Metformin effects to carbohydrate and lipids metabolism in impaired glucose tolerance patients.
by: Alexander Vasil'evich Dreval', et al.
Published: (2010-06-01)

Effect of Aqueous and Ethanolic Extract of Syzygium Aromaticum on Blood Glucose in Diabetic Rats
by: Zunnera Rashid Chaudhry , Asif Naseer , Erum Rasheed Chaudhry , Sana Rasheed Chaudhry
Published: (2015-09-01)

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation
by: N Waugh, et al.
Published: (2010-07-01)

Evaluation of Serum Insulin, Glucose and Liver Function in β-Thalassemia Major and Their Correlation with Iron Overload
by: Basma Matar, et al.
Published: (2021-01-01)

Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
by: Ehtasham Ahmad, et al.
Published: (2020-11-01)

Metformin and Cancer Glucose Metabolism: At the Bench or at the Bedside?
by: Cecilia Marini, et al.
Published: (2021-08-01)

The Effect of Metformine on Glucose Control in Patients with Diabetes Type 1
by: Amir Ziaee, et al.
Published: (2010-09-01)

Metformin Targets Foxo1 to Control Glucose Homeostasis
by: Xiaoqin Guo, et al.
Published: (2021-06-01)

The Influence of Diet Change and Oral Metformin on Blood Glucose Regulation and the Fecal Microbiota of Healthy Horses
by: Aaron C. Ericsson, et al.
Published: (2021-04-01)

Metformin Mitigates Fibrosis and Glucose Intolerance Induced by Doxorubicin in Subcutaneous Adipose Tissue
by: Luana A. Biondo, et al.
Published: (2018-05-01)

Metformin is a potential therapeutic for COVID-19/LUAD by regulating glucose metabolism
by: Yongwang Hou, et al.
Published: (2024-05-01)

Metformin limits apoptosis in primary rat cortical astrocytes subjected to oxygen and glucose deprivation
by: Bożena Gabryel, et al.
Published: (2018-12-01)

COVID-19 newer and emerging treatment options
by: Suneetha Narreddy, et al.
Published: (2021-01-01)

Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study
by: Arielle Mendel, et al.
Published: (2023-07-01)

Sodium-glucose cotransporter-2 inhibitors in combination with other glucose-lowering agents for the treatment of type 2 diabetes mellitus
by: Sanjay Kalra, et al.
Published: (2018-01-01)

Glyceraldehyde derivatives inspired by empagliflozin as potential anti-heart failure agents independent of glucose-lowering effects
by: Xiao Li, et al.
Published: (2024-05-01)

Metformin acts as a dual glucose regulator in mouse brain
by: Bo-Yeong Jin, et al.
Published: (2023-04-01)

Effects of exercise and metformin on the prevention of glucose intolerance: a comparative study
by: C. Molena-Fernandes, et al.
Published: (2015-12-01)

Effects of exercise and metformin on the prevention of glucose intolerance: a comparative study
by: C. Molena-Fernandes, et al.
Published: (2015-09-01)

Low glucose availability potentiates the effects of metformin on model T cell activation and exhaustion markers in vitro
by: Jernej Repas, et al.
Published: (2023-12-01)

Lycopene Improves the Metformin Effects on Blood Glucose and Neutrophil Counts in Type 2 Diabetic Rats
by: Medina Sianturi, et al.
Published: (2023-04-01)

CARDIOVASCULAR COMPLICATIONS AND CARBOHYDRATE METABOLISM IN CORONARY SHUNTING “OFF-PUMP” ACCORDING TO THE REGIMEN OF GLUCOSE LOWERING TREATMENT IN ISCHEMIC HEART DISEASE AND DIABETES
by: S. Yu. Borodashkina, et al.
Published: (2016-02-01)

Association of glucose-lowering drug target and risk of gastrointestinal cancer: a mendelian randomization study
by: Yi Yang, et al.
Published: (2024-03-01)